A Phase 1 interventional study of AlloRx in Congestive Heart Failure and Angina, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Terminated at 2 sites in 2 countries. Per ClinicalTrials.gov, last updated 2025-04-06.
Sponsored by The Foundation for Orthopaedics and Regenerative Medicine · Phase 1, Interventional, and Treatment
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of congestive heart failure and angina
This patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs) for the treatment of congestive heart failure and angina. Patients will receive a single intravenous infusion of UC-MSCs. The total dose will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.
For patients with more severe disease an autologous Effector cells (activated lymphocytes) treatment will be utilized created from the patient's own cells obtained by apheresis.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's enrollment of 3 is below the median of 72 across 3,736 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →The Foundation for Orthopaedics and Regenerative Medicine is the lead sponsor of 33 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Single intravenous infusion of 100 million cells
Biological: AlloRx
cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Safety (adverse events)
Clinical monitoring of possible adverse events or complications
Time frame: Four year follow-up
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Foundation for Orthopaedics and Regenerative Medicine